Reviva Pharmaceuticals I... (RVPH)
1.72
0.14 (8.86%)
At close: Jan 15, 2025, 3:07 PM
undefined% (undefined)
| Bid | 1.71 |
| Market Cap | 80.00M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.08 |
| PE Ratio (ttm) | -1.59 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.73 |
| Volume | 411,355 |
| Avg. Volume (20D) | 2,591,908 |
| Open | 1.66 |
| Previous Close | 1.58 |
| Day's Range | 1.61 - 1.75 |
| 52-Week Range | 0.60 - 4.83 |
| Beta | undefined |
About RVPH
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 18, 2018
Employees 15
Stock Exchange NASDAQ
Ticker Symbol RVPH
Website https://revivapharma.com
Analyst Forecast
According to 6 analyst ratings, the average rating for RVPH stock is "Buy." The 12-month stock price forecast is $14.5, which is an increase of 744.20% from the latest price.
Buy 66.67%
Hold 0.00%
Sell 0.00%
4 weeks ago ·
Source
-39.13%
Reviva Pharmaceuticals shares are trading lower af...
Unlock content with
Pro Subscription
2 months ago ·
Source
+32%
Reviva Pharmaceuticals Holdings shares are trading higher after the company announced an enrollment update to the ongoing 1-year open-label extension study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia.
